サマリー
このレポートはデジタルヘルス市場の主要な動向や市場機会、展望などのエコシステムを下記の項目ごとに分析しています。
-
テレヘルスとテレメディスン
-
遠隔患者モニタリング
-
デジタル治療(デジセウティカル)、医療デバイスとしてのソフトウェア
-
糖尿病管理
-
消費者向け遺伝子テスト
-
介護者としてのスマートホーム
-
医療診断におけるAI
Report Details
Digital health and artificial intelligence (AI) promises to change the face of healthcare. Reflecting this is growing interest in the digital health space, as evidenced by a substantial growth in investment over the past few years. Major players from the pharmaceutical, medtech, health insurance, retail and technology industries are all forging ahead with investments and internal product development.
Digital health is a convoluted and complex field, much of which is made up of technologies and services that enable healthcare outside of traditional clinical settings. It follows a global trend in the healthcare industry of decentralization to alleviate overburdened hospitals and clinics. Coupled with escalating healthcare costs, shrinking profit margins and ageing populations suffering with chronic conditions, digital health offers a solution to these problems for all players in the space including patients, providers and payers. In fact, it presents such an alluring and lucrative opportunity that companies not previously in the healthcare space are making significant investments and moves to do so. Big tech companies such as Amazon, Apple, Alphabet and Microsoft have continued to make significant strides into the healthcare space since their announcements in January 2018.
The time is ripe for digital health due to the combination of a number of factors. These include changing population demographics, as well as current and upcoming changes to regulations and reimbursements which mean that the route to market and take-up of digital health services and technologies is more likely. Rising capabilities in artificial intelligence, connectivity and technologies such as continuous glucose monitoring enable new forms of health communication, patient treatment and monitoring, and streamlining of healthcare services.
Telemedicine, referring to the remote delivery of healthcare services using technology, is seeing rising demand. Benefits of telemedicine include increased convenience to patients, improved quality of care, improved outcomes, and cost savings. Telemedicine and remote patient monitoring technologies enable patients to leave the hospital earlier and to stay healthy at home for longer. On the other hand, physicians benefit from the broader use of technology in telehealth, including improved communication between practitioners, access to specialists, and even remote training.
By whichever name it comes under, whether that's digiceuticals, digital therapeutics or software-as-a-drug, this idea of software replacing drugs is a worry for large, established pharmaceutical companies. Coupled with the changing landscape of healthcare which is moving away from treating patients and towards a model of preventative care and a move from fee-based to value-based services, healthcare delivery is being disrupted and digital health threatens to cause even more turbulence.
Artificial intelligence (AI) is revolutionizing medical diagnostics. The state-of-the-art results have already demonstrated that software can achieve fast and accurate image-based diagnostics on various conditions affecting the skin, eye, hear, lung, breast, and so on. These technological advancements can help automate the diagnosis and triage processes, accelerating the process to speed up the referral process especially in urgent cases, freeing up expert resources, offering the best accuracy everywhere regardless of skill levels, and making the processes more widely available. This is a ground-breaking development with far-reaching consequences. Naturally, many innovators are scrambling to capitalize on these advancements.
This report outlines the state-of-the-art in AI-based diagnosis of various conditions affecting the skin, eye, heart, breast, brain, lung, blood, genetic disorder, and so. The data sources employed are diverse including dermoscopic images, fundus images, OCT, CT, CTA, echocardiograms, electrocardiogram , mammography, pathology slides, low-res mobile phone pictures, and so on. This report then identifies and highlights companies seeking to capitalize on these technology advances to automate the diagnostic and triage process.
This report provides a detailed overview of the digital health ecosystem including insights into the key trends, opportunities and outlooks for all aspects of digital health, including:
• Telehealth and telemedicine
• Remote patient monitoring
• Digital therapeutics / digiceuticals / software as a medical device
• Diabetes management
• Consumer genetic testing
• Smart home as a carer
• AI in diagnostics
ページTOPに戻る
目次
Table of Contents
|
1. |
EXECUTIVE SUMMARY & CONCLUSIONS |
|
1.1. |
The Scope of Digital Health |
|
1.2. |
Changing Demographics Require Healthcare Reforms |
|
1.3. |
Factors Encouraging the Rise of Digital Health |
|
1.4. |
Enabling Technologies for Digital Health |
|
1.5. |
Effective Use of Resources Enabling Cost Efficiency |
|
1.6. |
The Future of Healthcare is Consumer-Led |
|
1.7. |
Big Tech Players are Moving into Healthcare |
|
1.8. |
Towards a Model of Value-Based Healthcare |
|
1.9. |
Big Pharma is Struggling, Disruption is Inevitable |
|
1.10. |
Consolidating and Collaborating to Survive and Thrive |
|
1.11. |
Regulation of Digital Health: Wanting the Best of Both Worlds |
|
1.12. |
Telehealth and Telemedicine are Poised for Take-Off |
|
1.13. |
The Future for Telehealth and Telemedicine |
|
1.14. |
Remote Patient Monitoring is Changing the Face of Healthcare |
|
1.15. |
The Outlook for Remote Patient Monitoring |
|
1.16. |
Digital Therapeutics - The Next Step for mHealth? |
|
1.17. |
The Outlook for Digital Therapeutics |
|
1.18. |
The Rise of Direct-to-Consumer Genetic Testing |
|
1.19. |
Sensors in Smart Homes: Decentralization of Healthcare |
|
1.20. |
Funding and IPOs |
|
1.21. |
Market Outlook: Wearable Medical Devices |
|
1.22. |
Outlook for Digital Health: Quality, Outcomes, and Value are Key |
|
2. |
INTRODUCTION |
|
2.1. |
The Scope of Digital Health |
|
2.2. |
Digital Health Definitions |
|
2.3. |
Changing Demographics Require Healthcare Reforms |
|
2.4. |
Global Healthcare Spending is Rising |
|
2.5. |
Margins are Being Squeezed in Healthcare |
|
2.6. |
Trouble for Traditional Healthcare? |
|
2.7. |
Mergers and Acquisitions: Vertical Integration |
|
2.8. |
Big Tech Players are Moving into Healthcare |
|
2.9. |
Apple - 2018 Update |
|
2.10. |
Apple - 2019 Update |
|
2.11. |
Amazon |
|
2.12. |
Amazon - Alexa |
|
2.13. |
Alphabet |
|
2.14. |
Microsoft |
|
2.15. |
Tencent |
|
2.16. |
From Fee-for-Service to Value-Based Purchasing |
|
2.17. |
Towards a Model of Value-Based Healthcare |
|
2.18. |
Big Pharma is Struggling |
|
2.19. |
Digital Disruptors & Big Pharma: A Match Made in Heaven? |
|
2.20. |
Big Pharma: Competitions and Digital Hubs |
|
2.21. |
The Future for Pharma |
|
2.22. |
Rising Role of Venture Capital |
|
2.23. |
Funding and IPOs |
|
2.24. |
Mobile Health is Becoming the Norm |
|
2.25. |
Apple Enters the Electronic Health Record Market |
|
2.26. |
The Future of Healthcare is Consumer-Led |
|
2.27. |
Apps are Moving Towards Voice |
|
2.28. |
A Move to Precision/Personalized Medicine |
|
2.29. |
Biosensors are Moving to the Point-of-Care |
|
2.30. |
Consumer-Driven, Patient Centered Healthcare |
|
2.31. |
Global Challenges in Implementing Digital Health |
|
2.32. |
The P4 Healthcare Model |
|
2.33. |
The Emergence of a P4 Healthcare System |
|
2.34. |
Wellness and Prevention |
|
2.35. |
Market Outlook: Wearable Medical Devices |
|
3. |
ENABLING TECHNOLOGIES |
|
3.1. |
Enabling Technologies for Digital Health |
|
3.2. |
IoT |
|
3.3. |
5G |
|
3.4. |
Access to High Quality Broadband |
|
3.5. |
Artificial Intelligence and Machine Learning |
|
3.6. |
VR, AR and MR |
|
4. |
REGULATIONS AND SECURITY |
|
4.1. |
Digital vs Traditional Healthcare |
|
4.2. |
Medical Device Pathways |
|
4.3. |
Regulation of Digital Therapeutics |
|
4.4. |
FDA Pre-Cert Program |
|
4.5. |
Pre-Cert 1.0 |
|
4.6. |
Digital Tools Not Under FDA Review |
|
4.7. |
Regulation of Direct-to-Consumer Genetic Testing |
|
4.8. |
Genetic Data, Privacy Concerns and a Lack of Trust |
|
4.9. |
Unanswered questions about device security |
|
4.10. |
Security Risks for Medical Devices |
|
4.11. |
The Security of Data is a Critical Issue |
|
4.12. |
National Systems at Risk of Large-Scale Cyber Attacks |
|
5. |
TELEHEALTH & TELEMEDICINE |
|
5.1. |
Defining Telehealth and Telemedicine |
|
5.2. |
Telehealth Encompasses a Range of Services |
|
5.3. |
There are Numerous Types of Telemedicine |
|
5.4. |
The Key Services Models for Telehealth |
|
5.5. |
Use Cases for Telehealth and Telemedicine |
|
5.6. |
Benefits of Telehealth and Telemedicine |
|
5.7. |
Challenges in Telehealth and Telemedicine |
|
5.8. |
Is Telehealth a Cost-Effective Solution? |
|
5.9. |
Telehealth and Telemedicine are Poised for Take-Off |
|
5.10. |
The Growing Network of Care |
|
5.11. |
Doctors Require Better Ways of Communication |
|
5.12. |
Nomadeec |
|
5.13. |
Smartphones Become the Tool for Doctors |
|
5.14. |
Driving the Uptake of Telemedicine |
|
5.15. |
Changes to Reimbursement of Telehealth |
|
5.16. |
Reimbursement of Remote Patient Monitoring |
|
5.17. |
Room to Improve and Mature |
|
5.18. |
The Next-Generation of Telemedicine |
|
5.19. |
Can AI Replace Your Doctor? |
|
5.20. |
Babylon Health |
|
5.21. |
TytoCare |
|
5.22. |
American Well |
|
5.23. |
Key American Well Partnerships |
|
5.24. |
The Future for Telehealth and Telemedicine |
|
5.25. |
The Future for Telehealth and Telemedicine (cont.) |
|
6. |
REMOTE PATIENT MONITORING |
|
6.1. |
Remote Patient Monitoring: Measurements and Applications |
|
ページTOPに戻る
Summary
このレポートはデジタルヘルス市場の主要な動向や市場機会、展望などのエコシステムを下記の項目ごとに分析しています。
-
テレヘルスとテレメディスン
-
遠隔患者モニタリング
-
デジタル治療(デジセウティカル)、医療デバイスとしてのソフトウェア
-
糖尿病管理
-
消費者向け遺伝子テスト
-
介護者としてのスマートホーム
-
医療診断におけるAI
Report Details
Digital health and artificial intelligence (AI) promises to change the face of healthcare. Reflecting this is growing interest in the digital health space, as evidenced by a substantial growth in investment over the past few years. Major players from the pharmaceutical, medtech, health insurance, retail and technology industries are all forging ahead with investments and internal product development.
Digital health is a convoluted and complex field, much of which is made up of technologies and services that enable healthcare outside of traditional clinical settings. It follows a global trend in the healthcare industry of decentralization to alleviate overburdened hospitals and clinics. Coupled with escalating healthcare costs, shrinking profit margins and ageing populations suffering with chronic conditions, digital health offers a solution to these problems for all players in the space including patients, providers and payers. In fact, it presents such an alluring and lucrative opportunity that companies not previously in the healthcare space are making significant investments and moves to do so. Big tech companies such as Amazon, Apple, Alphabet and Microsoft have continued to make significant strides into the healthcare space since their announcements in January 2018.
The time is ripe for digital health due to the combination of a number of factors. These include changing population demographics, as well as current and upcoming changes to regulations and reimbursements which mean that the route to market and take-up of digital health services and technologies is more likely. Rising capabilities in artificial intelligence, connectivity and technologies such as continuous glucose monitoring enable new forms of health communication, patient treatment and monitoring, and streamlining of healthcare services.
Telemedicine, referring to the remote delivery of healthcare services using technology, is seeing rising demand. Benefits of telemedicine include increased convenience to patients, improved quality of care, improved outcomes, and cost savings. Telemedicine and remote patient monitoring technologies enable patients to leave the hospital earlier and to stay healthy at home for longer. On the other hand, physicians benefit from the broader use of technology in telehealth, including improved communication between practitioners, access to specialists, and even remote training.
By whichever name it comes under, whether that's digiceuticals, digital therapeutics or software-as-a-drug, this idea of software replacing drugs is a worry for large, established pharmaceutical companies. Coupled with the changing landscape of healthcare which is moving away from treating patients and towards a model of preventative care and a move from fee-based to value-based services, healthcare delivery is being disrupted and digital health threatens to cause even more turbulence.
Artificial intelligence (AI) is revolutionizing medical diagnostics. The state-of-the-art results have already demonstrated that software can achieve fast and accurate image-based diagnostics on various conditions affecting the skin, eye, hear, lung, breast, and so on. These technological advancements can help automate the diagnosis and triage processes, accelerating the process to speed up the referral process especially in urgent cases, freeing up expert resources, offering the best accuracy everywhere regardless of skill levels, and making the processes more widely available. This is a ground-breaking development with far-reaching consequences. Naturally, many innovators are scrambling to capitalize on these advancements.
This report outlines the state-of-the-art in AI-based diagnosis of various conditions affecting the skin, eye, heart, breast, brain, lung, blood, genetic disorder, and so. The data sources employed are diverse including dermoscopic images, fundus images, OCT, CT, CTA, echocardiograms, electrocardiogram , mammography, pathology slides, low-res mobile phone pictures, and so on. This report then identifies and highlights companies seeking to capitalize on these technology advances to automate the diagnostic and triage process.
This report provides a detailed overview of the digital health ecosystem including insights into the key trends, opportunities and outlooks for all aspects of digital health, including:
• Telehealth and telemedicine
• Remote patient monitoring
• Digital therapeutics / digiceuticals / software as a medical device
• Diabetes management
• Consumer genetic testing
• Smart home as a carer
• AI in diagnostics
ページTOPに戻る
Table of Contents
Table of Contents
|
1. |
EXECUTIVE SUMMARY & CONCLUSIONS |
|
1.1. |
The Scope of Digital Health |
|
1.2. |
Changing Demographics Require Healthcare Reforms |
|
1.3. |
Factors Encouraging the Rise of Digital Health |
|
1.4. |
Enabling Technologies for Digital Health |
|
1.5. |
Effective Use of Resources Enabling Cost Efficiency |
|
1.6. |
The Future of Healthcare is Consumer-Led |
|
1.7. |
Big Tech Players are Moving into Healthcare |
|
1.8. |
Towards a Model of Value-Based Healthcare |
|
1.9. |
Big Pharma is Struggling, Disruption is Inevitable |
|
1.10. |
Consolidating and Collaborating to Survive and Thrive |
|
1.11. |
Regulation of Digital Health: Wanting the Best of Both Worlds |
|
1.12. |
Telehealth and Telemedicine are Poised for Take-Off |
|
1.13. |
The Future for Telehealth and Telemedicine |
|
1.14. |
Remote Patient Monitoring is Changing the Face of Healthcare |
|
1.15. |
The Outlook for Remote Patient Monitoring |
|
1.16. |
Digital Therapeutics - The Next Step for mHealth? |
|
1.17. |
The Outlook for Digital Therapeutics |
|
1.18. |
The Rise of Direct-to-Consumer Genetic Testing |
|
1.19. |
Sensors in Smart Homes: Decentralization of Healthcare |
|
1.20. |
Funding and IPOs |
|
1.21. |
Market Outlook: Wearable Medical Devices |
|
1.22. |
Outlook for Digital Health: Quality, Outcomes, and Value are Key |
|
2. |
INTRODUCTION |
|
2.1. |
The Scope of Digital Health |
|
2.2. |
Digital Health Definitions |
|
2.3. |
Changing Demographics Require Healthcare Reforms |
|
2.4. |
Global Healthcare Spending is Rising |
|
2.5. |
Margins are Being Squeezed in Healthcare |
|
2.6. |
Trouble for Traditional Healthcare? |
|
2.7. |
Mergers and Acquisitions: Vertical Integration |
|
2.8. |
Big Tech Players are Moving into Healthcare |
|
2.9. |
Apple - 2018 Update |
|
2.10. |
Apple - 2019 Update |
|
2.11. |
Amazon |
|
2.12. |
Amazon - Alexa |
|
2.13. |
Alphabet |
|
2.14. |
Microsoft |
|
2.15. |
Tencent |
|
2.16. |
From Fee-for-Service to Value-Based Purchasing |
|
2.17. |
Towards a Model of Value-Based Healthcare |
|
2.18. |
Big Pharma is Struggling |
|
2.19. |
Digital Disruptors & Big Pharma: A Match Made in Heaven? |
|
2.20. |
Big Pharma: Competitions and Digital Hubs |
|
2.21. |
The Future for Pharma |
|
2.22. |
Rising Role of Venture Capital |
|
2.23. |
Funding and IPOs |
|
2.24. |
Mobile Health is Becoming the Norm |
|
2.25. |
Apple Enters the Electronic Health Record Market |
|
2.26. |
The Future of Healthcare is Consumer-Led |
|
2.27. |
Apps are Moving Towards Voice |
|
2.28. |
A Move to Precision/Personalized Medicine |
|
2.29. |
Biosensors are Moving to the Point-of-Care |
|
2.30. |
Consumer-Driven, Patient Centered Healthcare |
|
2.31. |
Global Challenges in Implementing Digital Health |
|
2.32. |
The P4 Healthcare Model |
|
2.33. |
The Emergence of a P4 Healthcare System |
|
2.34. |
Wellness and Prevention |
|
2.35. |
Market Outlook: Wearable Medical Devices |
|
3. |
ENABLING TECHNOLOGIES |
|
3.1. |
Enabling Technologies for Digital Health |
|
3.2. |
IoT |
|
3.3. |
5G |
|
3.4. |
Access to High Quality Broadband |
|
3.5. |
Artificial Intelligence and Machine Learning |
|
3.6. |
VR, AR and MR |
|
4. |
REGULATIONS AND SECURITY |
|
4.1. |
Digital vs Traditional Healthcare |
|
4.2. |
Medical Device Pathways |
|
4.3. |
Regulation of Digital Therapeutics |
|
4.4. |
FDA Pre-Cert Program |
|
4.5. |
Pre-Cert 1.0 |
|
4.6. |
Digital Tools Not Under FDA Review |
|
4.7. |
Regulation of Direct-to-Consumer Genetic Testing |
|
4.8. |
Genetic Data, Privacy Concerns and a Lack of Trust |
|
4.9. |
Unanswered questions about device security |
|
4.10. |
Security Risks for Medical Devices |
|
4.11. |
The Security of Data is a Critical Issue |
|
4.12. |
National Systems at Risk of Large-Scale Cyber Attacks |
|
5. |
TELEHEALTH & TELEMEDICINE |
|
5.1. |
Defining Telehealth and Telemedicine |
|
5.2. |
Telehealth Encompasses a Range of Services |
|
5.3. |
There are Numerous Types of Telemedicine |
|
5.4. |
The Key Services Models for Telehealth |
|
5.5. |
Use Cases for Telehealth and Telemedicine |
|
5.6. |
Benefits of Telehealth and Telemedicine |
|
5.7. |
Challenges in Telehealth and Telemedicine |
|
5.8. |
Is Telehealth a Cost-Effective Solution? |
|
5.9. |
Telehealth and Telemedicine are Poised for Take-Off |
|
5.10. |
The Growing Network of Care |
|
5.11. |
Doctors Require Better Ways of Communication |
|
5.12. |
Nomadeec |
|
5.13. |
Smartphones Become the Tool for Doctors |
|
5.14. |
Driving the Uptake of Telemedicine |
|
5.15. |
Changes to Reimbursement of Telehealth |
|
5.16. |
Reimbursement of Remote Patient Monitoring |
|
5.17. |
Room to Improve and Mature |
|
5.18. |
The Next-Generation of Telemedicine |
|
5.19. |
Can AI Replace Your Doctor? |
|
5.20. |
Babylon Health |
|
5.21. |
TytoCare |
|
5.22. |
American Well |
|
5.23. |
Key American Well Partnerships |
|
5.24. |
The Future for Telehealth and Telemedicine |
|
5.25. |
The Future for Telehealth and Telemedicine (cont.) |
|
6. |
REMOTE PATIENT MONITORING |
|
6.1. |
Remote Patient Monitoring: Measurements and Applications |
|
ページTOPに戻る
本レポートと同じKEY WORD（デジタルヘルス）の最新刊レポート
- 本レポートと同じKEY WORDの最新刊レポートはありません。
よくあるご質問
IDTechEx社はどのような調査会社ですか?
IDTechExはセンサ技術や3D印刷、電気自動車などの先端技術・材料市場を対象に広範かつ詳細な調査を行っています。データリソースはIDTechExの調査レポートおよび委託調査（個別調査）を取り扱う日... もっと見る
調査レポートの納品までの日数はどの程度ですか?
在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。
注文の手続きはどのようになっていますか?
1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。
お支払方法の方法はどのようになっていますか?
納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。
データリソース社はどのような会社ですか?
当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。
|
|
ページTOPに戻る
|
